Business Description
BioNTech SE
ISIN : US09075V1026
Share Class Description:
FRA:22UA: ADRCompare
Compare
Traded in other countries / regions
BNTX.USA22UA.Germany0A3M.UKB1NT34.BrazilBNTX.MexicoBNTX.Austria IPO Date
2019-10-10Description
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 75.53 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.2 | |||||
| Interest Coverage | 25.41 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 6.59 | |||||
| Beneish M-Score | -2.66 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 93.7 | |||||
| 3-Year EPS without NRI Growth Rate | 151.4 | |||||
| 3-Year Book Growth Rate | 137.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -31.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | -35.59 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.15 | |||||
| 9-Day RSI | 40.35 | |||||
| 14-Day RSI | 41.98 | |||||
| 6-1 Month Momentum % | -3.49 | |||||
| 12-1 Month Momentum % | -22.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.43 | |||||
| Quick Ratio | 9.26 | |||||
| Cash Ratio | 7.99 | |||||
| Days Inventory | 252.61 | |||||
| Days Sales Outstanding | 387.28 | |||||
| Days Payable | 126.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.5 | |||||
| Shareholder Yield % | 3.87 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.28 | |||||
| Operating Margin % | 23.64 | |||||
| Net Margin % | 24.34 | |||||
| FCF Margin % | 122.18 | |||||
| ROE % | 4.65 | |||||
| ROA % | 4.14 | |||||
| ROIC % | 10.29 | |||||
| ROC (Joel Greenblatt) % | 25.49 | |||||
| ROCE % | 4.5 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 20.94 | |||||
| PE Ratio without NRI | 18.82 | |||||
| Price-to-Owner-Earnings | 2.96 | |||||
| PS Ratio | 5.06 | |||||
| PB Ratio | 0.93 | |||||
| Price-to-Tangible-Book | 0.98 | |||||
| Price-to-Free-Cash-Flow | 4.09 | |||||
| Price-to-Operating-Cash-Flow | 3.56 | |||||
| EV-to-EBIT | 2.98 | |||||
| EV-to-Forward-EBIT | -2.44 | |||||
| EV-to-EBITDA | 2.49 | |||||
| EV-to-Forward-EBITDA | -2.85 | |||||
| EV-to-Revenue | 0.72 | |||||
| EV-to-Forward-Revenue | 1.03 | |||||
| EV-to-FCF | 0.58 | |||||
| Price-to-Graham-Number | 0.91 | |||||
| Price-to-Net-Current-Asset-Value | 1.12 | |||||
| Price-to-Net-Cash | 1.36 | |||||
| Earnings Yield (Greenblatt) % | 33.56 | |||||
| FCF Yield % | 24.36 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioNTech SE Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3,819 | ||
| EPS (TTM) (€) | 3.82 | ||
| Beta | 1.1 | ||
| Volatility % | 25.82 | ||
| 14-Day RSI | 41.98 | ||
| 14-Day ATR (€) | 2.484258 | ||
| 20-Day SMA (€) | 83.4865 | ||
| 12-1 Month Momentum % | -22.99 | ||
| 52-Week Range (€) | 77.5 - 116 | ||
| Shares Outstanding (Mil) | 240.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioNTech SE Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioNTech SE Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioNTech SE Frequently Asked Questions
What is BioNTech SE(FRA:22UA)'s stock price today?
The current price of FRA:22UA is €81.20. The 52 week high of FRA:22UA is €116.00 and 52 week low is €77.50.
When is next earnings date of BioNTech SE(FRA:22UA)?
The next earnings date of BioNTech SE(FRA:22UA) is 2024-05-08 Est..
Does BioNTech SE(FRA:22UA) pay dividends? If so, how much?
BioNTech SE(FRA:22UA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers